Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sumitomo Pharma America, Inc.
Celgene
Celgene